Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 in Healthy Volunteers
April 29 2024 - 8:00AM
Bitterroot Bio, a leader in developing innovative medicines in the
field of cardio-immunology, today announced that the first human
participants have been dosed in a Phase 1 study of BRB-002 in
healthy volunteers.
BRB-002 is a novel protein therapy targeting
CD47 that is being investigated as a potential treatment option for
patients with atherosclerotic cardiovascular disease (ASCVD).
The Phase 1 trial is evaluating the safety and
tolerability of subcutaneously administered BRB-002 in healthy
volunteers. Bitterroot Australia Pty Ltd, a wholly owned subsidiary
of Bitterroot Bio, Inc., is directing this clinical trial in
partnership with the Nucleus Network in Brisbane.
"The initiation of this Phase 1 trial is a
vital step forward in our mission to address unmet cardiovascular
needs, and marks Bitterroot’s transformation into a clinical-stage
company," said Craig Basson, MD, PhD, Chief Medical Officer of
Bitterroot Bio. "This milestone reflects our team's hard work and
dedication to advancing cardiovascular science by developing a
novel medicine in ASCVD. We are optimistic about the potential of
BRB-002 to make a meaningful difference in the lives of patients
and are committed to rigorously evaluating its safety and efficacy
in the clinic."
About BRB-002BRB-002 is a novel
protein therapy that is being evaluated as an investigational agent
in atherosclerotic cardiovascular disease (ASCVD). BRB-002 inhibits
the CD47 cell surface receptor ("don’t eat me" signal) to address
the underlying causes of atherosclerosis and vascular inflammation.
In preclinical studies, BRB-002 has been shown to attenuate
atherosclerosis in both prevention and established disease models.
BRB-002 is currently being investigated in a Phase 1 clinical
study.
About Bitterroot BioBitterroot Bio, Inc. is a
pioneer in the emerging field of cardio-immunology, which
investigates the interplay between the immune system and
cardiovascular health. Bitterroot Bio’s research discoveries have
uncovered critical roles that immune cells and modulators of
inflammation play in the initiation and progression of
cardiovascular disease. Our ultimate goal is to provide new hope to
those suffering from cardiovascular diseases by transforming the
way these diseases are treated.
For more information, please visit https://www.brbio.com
Media Contact:Emily Dale (Bitterroot Bio),
media@brbio.com